Pfizer's (PFE) Xalkori (crizotinib) — approved in August of 2011 for the treatment of non-small...

|About: Pfizer Inc. (PFE)|By:, SA News Editor

Pfizer's (PFE) Xalkori (crizotinib) — approved in August of 2011 for the treatment of non-small cell lung cancer patients who are ALK-positive — shows promise in extending progression-free survival when compared with the chemotherapy drugs pemetrexed and docetaxel, data from a clinical trial shows. The drug had sales of $53M in Q1. (WSJ)